T-Minus COVID-19 – Impact of Pandemic on New Medicine Launches
Eye on FDA
APRIL 15, 2020
But a new drug launch in the time of COVID-19 comes with definite challenges. Bristol Myers Squibb stated in its press release announcing FDA approval of the company’s treatment for multiple sclerosis that the commercial launch would be delayed due to the COVID-19 situation. Recently in the U.S.
Let's personalize your content